The title of the article is Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. The article was published on Vaccine in May 2021. The first author is Elmar A. Joura. The study aims to compare the efficacy and safety of 9-valent HPV vaccine in women aged 27-45 years to women aged 16 – 26 years. The study was an international study conducted in 6 countries (Austria, Belgium, Finland, Germany, Italy, and Spain). Participants were enrolled in two age groups: women aged 16-26, and women aged 27-45. A total of 1210 participants were enrolled. All patients were previously healthy adults, and they all received 3 doses of HPV vaccine on day 1, month 2, and month 6. The immunogenicity was evaluated by month 7 geometric mean titers (GMTs) and seroconversion percentages to anti HPV strands. The authors found that after administering 9vHPV vaccines, the antibody responses to HPV were non-inferior in older adults. In addition, more than 99% of participants seroconverted to all 9 HPV types at month 7. The vaccine is well-tolerated, and the vaccine’s safety profile was similar between the 2 age groups. In conclusion, the 9vHPV vaccine could provide broad protection against HPV infection in adult women aged 26-45.
